Each of our selected target proteins also represents an established or emerging therapeutic target: selective NOX4 inhibitors (GKT137831/Setanaxib) are in clinical development [32]; EGFR and PDGFR inhibitors are FDA-approved for multiple cancers [33]; and OCTN2 is increasingly recognized as a target for enhancing drug delivery and regulating cancer cell metabolism [34]. Here, SLC22A5 is linked to cancer.